DrugPatentWatch Database Preview

MAVYRET Drug Profile

« Back to Dashboard

When do Mavyret patents expire, and when can generic versions of Mavyret launch?

Mavyret is a drug marketed by Abbvie Inc and is included in one NDA. There are seven patents protecting this drug.

This drug has three hundred and eighty-three patent family members in forty-four countries.

The generic ingredient in MAVYRET is glecaprevir; pibrentasvir. One supplier is listed for this compound. Additional details are available on the glecaprevir; pibrentasvir profile page.

Summary for MAVYRET

International Patents:	383
US Patents:	7
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Clinical Trials:	5
Drug Prices:	Drug price information for MAVYRET
DailyMed Link:	MAVYRET at DailyMed

See drug prices for MAVYRET

Generic Entry Opportunity Date for MAVYRET

NDA:

209394

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MAVYRET

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Maryland	Early Phase 1
Massachusetts General Hospital	Phase 4
Raymond T. Chung, MD	Phase 4

See all MAVYRET clinical trials

Pharmacology for MAVYRET

Drug Class	Hepatitis C Virus NS5A Inhibitor Hepatitis C Virus NS3/4A Protease Inhibitor
Mechanism of Action	P-Glycoprotein Inhibitors Breast Cancer Resistance Protein Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors Cytochrome P450 3A Inhibitors Cytochrome P450 1A2 Inhibitors UGT1A1 Inhibitors HCV NS3/4A Protease Inhibitors

US Patents and Regulatory Information for MAVYRET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Inc	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes
Abbvie Inc	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes
Abbvie Inc	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes
Abbvie Inc	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes
Abbvie Inc	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes			Y	Y
Abbvie Inc	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes
Abbvie Inc	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes				Y

International Patents for MAVYRET

Country	Patent Number	Estimated Expiration
Japan	2013539791
Peru	00152014
China	103209686
South Korea	101990279
Singapore	10201708306W
Japan	2018162265
Canada	2828495

Supplementary Protection Certificates for MAVYRET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2618831	C20170035 00242	Estonia		PRODUCT NAME: GLEKAPREVIIR;REG NO/DATE: EU/1/17/1213 28.07.2017
2692346	LUC00038	Luxembourg		PRODUCT NAME: PIBRENTASVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728
2692346	2017/046	Ireland		PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2368890	92668	Luxembourg		PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119
2368890	C02368890/01	Switzerland		PRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014
2618831	PA2017034,C2618831	Lithuania		PRODUCT NAME: GLEKAPREVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA ESTERIS; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2618831	2017C/041	Belgium		PRODUCT NAME: GLECAPREVIR OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728